26.4 C
Vientiane
Friday, June 20, 2025
spot_img
Home Blog Page 771

MediBeacon® Transdermal GFR System receives device approval in China

Peer-reviewed articles on MediBeacon technology published

  • Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function.
  • The Clinical Kidney Journal in February published MediBeacon study results on measured GFR (mGFR) using relmapirazin versus estimated GFR (eGFR) for the purpose of classifying patient Chronic Kidney Disease (CKD) stages.
  • MediBeacon TGFR study results have been posted online in the February ahead of print section in the Journal of the American Society of Nephrology (JASN).

ST. LOUIS, Feb. 25, 2025 /PRNewswire/ — MediBeacon Inc. today announced the National Medical Products Administration (NMPA) in China has approved the MediBeacon® TGFR Monitor and TGFR Sensor for the assessment of kidney function in patients with normal or impaired renal function. Lumitrace® (relmapirazin) injection, categorized as a drug in China, is under review and is targeted for approval in late 2025. The transdermal GFR technology includes Lumitrace (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together with the TGFR Monitor and TGFR Sensor allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body.

In 2021, the NMPA granted the TGFR Innovative Medical Device Designation. Only 10% of applications are granted this designation. Benefits of this registration route including early product promotion are considerable.

In February, the Clinical Kidney Journal published MediBeacon data in an article on Chronic Kidney Disease (CKD) stage misclassification via estimated GFR (eGFR) compared to measured GFR (mGFR) using relmapirazin. In a stable CKD population, more than one-third of the subjects had an actual mGFR (relmapirazin) that differed by at least one CKD stage from their estimated GFR (eGFR).1  Relmapirazin is indicated for use with the TGFR.

“The Clinical Kidney Journal study raises serious concerns about how chronic kidney disease is diagnosed today,” said Dr. Ira Kurtz, Chief of the Division of Nephrology at UCLA Medical Center. “Researchers found that current eGFR methods misclassified 35% of patients, leading to potentially incorrect treatments and delayed interventions.”

In the February ahead of print section in the Journal of the American Society of Nephrology (JASN), MediBeacon clinical study data from the use of transdermal detection of relmapirazin in patients with normal to impaired kidney function across a range of skin color types was posted online.2 JASN publishes high-impact research to advance the understanding and treatment of kidney diseases.3

In addition to his leadership role at UCLA Medical Center, Dr. Kurtz is active in the development of an artificial kidney and artificial intelligence in the training and practice of nephrology.

Dr. Kurtz commented that: “The study in the Journal of the American Society of Nephrology introduces a wearable, transdermal device that assesses GFR without the need for blood samples. The fluorescence-based test, developed by MediBeacon, demonstrated an exceptional correlation (r² = 0.90) with plasma mGFR across all skin types, paving the way for more equitable and accurate kidney function assessment. These two new studies have reshaped the landscape of kidney disease diagnostics, offering both a cutting-edge innovation and a stark warning about current practices. The findings underscore the urgent need for improved kidney function assessment tools, with non-invasive, point of care GFR measurement emerging as a game-changing solution.”

“Awareness of kidney disease is relatively low despite the fact that it is the 7th leading risk factor for mortality worldwide.4 MediBeacon is pleased to have the opportunity to aid in the assessment of kidney function in China,” said Steve Hanley CEO of MediBeacon. “NMPA approval is the culmination of a rigorous device application process that required close collaboration of the MediBeacon and Huadong Medicine teams. We look forward to the next phase of our partnership with Huadong Medicine and eagerly anticipate Lumitrace approval in China later this year.”

The TGFR, which includes Lumitrace (relmapirazin), was approved on January 17th by the U.S. Food and Drug Administration (FDA). MediBeacon continues development of future TGFR products including a next-generation TGFR Sensor with updated software and algorithms.

About MediBeacon Inc.
MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 55 granted U.S. patents and over 215 granted patents worldwide that provide extensive coverage of the MediBeacon® TGFR, including Lumitrace® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR is approved for human use. Potential technology applications in gastroenterology, ophthalmology and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: www.medibeacon.com.

About Lumitrace® (relmapirazin) injection
Relmapirazin is a non-radioactive, non-iodinated pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al.5

About MediBeacon® Transdermal GFR System (TGFR) 
The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace® (relmapirazin), which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Sensor records 2.5 fluorescent readings per second and the TGFR Monitor will display the average session tGFR reading at the patient’s bedside or in the outpatient setting.

IMPORTANT SAFETY INFORMATION FOR TGFR (U.S. FDA)

Indication for Use:
The MediBeacon® Transdermal GFR System (TGFR) is intended to assess the Glomerular Filtration Rate (GFR) in adult patients with impaired or normal renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent over time. This device has been validated in patients with stable renal function.

The MediBeacon® TGFR is not approved for use in patients with GFR <15 ml/min/1.73 m2, GFR >120 ml/min/1.73m2, patients on dialysis, or anuric patients. The use of this device in patients with dynamic and rapidly changing renal function has not been validated. This device is not intended to diagnose acute kidney injury (AKI).

The MediBeacon® TGFR Sensor and exogenous tracer agent, Lumitrace® injection, are single use and are only used with the MediBeacon® TGFR.

The MediBeacon® TGFR Sensor is a single use device intended to attach to the patient’s skin and excite fluorescence in Lumitrace® injection, the tracer agent, and measure the returning light intensity. The data is sent to the MediBeacon® TGFR Monitor.

Lumitrace® is an injectable exogenous fluorescent tracer indicated for use with the MediBeacon® Transdermal GFR System (TGFR) for Glomerular Filtration Rate assessment.

Contraindications:
There are no known contraindications.

Warnings and Precautions:

  • See ifu.medibeacon.com for full instructions, warnings, and cautions.
  • In clinical studies no serious or severe adverse events have been observed.
  • Lumitrace® injection has light absorbance at 266nm and 435nm, and broad fluorescent emission at ~560nm when excited at ~440nm. Any drug activated at these wavelengths should not be used in conjunction with Lumitrace.
  • Lumitrace injection may interfere with clinical laboratory tests. DO NOT ADMINISTER if the patient is expected to need clinical laboratory testing while Lumitrace is present in their system (up to 72 hours for renally-impaired patients). The presence of Lumitrace decreased B-Type Natriuretic Peptide (BNP) results by around 20% in limited testing.
  • Bolus infusions may impact the GFR assessment temporarily while the vasculature-tissue equilibrium is re-established.
  • During a TGFR session, the patient should be as still as possible, especially during the “Establishing Baseline” stage. The current system is designed to compensate for light activity such as reading or eating after the Baseline stage.

1 CKD stage misclassification between estimated GFR and measured GFR in a clinical study of chronic kidney patients, Clinical Kidney Journal,  Dorshow, Richard B. et al., 2025 Jan 9;18(2):sfaf006. DOI: 10.1093/ckj/sfaf006
2 Glomerular Filtration Rate Measurement Utilizing Transdermal Detection Methodology, Journal of the American Society of Nephrology (JASN), Dorshow, Richard B. et al., February 7, 2025, DOI: 10.1681/ASN.0000000639
3 https://www.asn-online.org/publications/
4 Chronic kidney disease and the global public health agenda: an international consensus, Nature Reviews Nephrology, 20, 473-485 (2024), doi.org/10.1038/s41581-024-00820-6
5 Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102), Kidney International, Volume 106, Issue 4, P679-687, October 2024, DOI: 10.1016/j.kint.2024.06.012

MediBeacon® Transdermal GFR System receives device approval in China; Peer-reviewed articles on MediBeacon technology published

  • Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function.
  • The Clinical Kidney Journal in February published MediBeacon study results on measured GFR (mGFR) using relmapirazin versus estimated GFR (eGFR) for the purpose of classifying patient Chronic Kidney Disease (CKD) stages.
  • MediBeacon TGFR study results have been posted online in the February ahead of print section in the Journal of the American Society of Nephrology (JASN).

ST. LOUIS, Feb. 25, 2025 /PRNewswire/ — MediBeacon Inc. today announced the National Medical Products Administration (NMPA) in China has approved the MediBeacon® TGFR Monitor and TGFR Sensor for the assessment of kidney function in patients with normal or impaired renal function. Lumitrace® (relmapirazin) injection, categorized as a drug in China, is under review and is targeted for approval in late 2025. The transdermal GFR technology includes Lumitrace (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together with the TGFR Monitor and TGFR Sensor allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body.

In 2021, the NMPA granted the TGFR Innovative Medical Device Designation. Only 10% of applications are granted this designation. Benefits of this registration route including early product promotion are considerable.

In February, the Clinical Kidney Journal published MediBeacon data in an article on Chronic Kidney Disease (CKD) stage misclassification via estimated GFR (eGFR) compared to measured GFR (mGFR) using relmapirazin. In a stable CKD population, more than one-third of the subjects had an actual mGFR (relmapirazin) that differed by at least one CKD stage from their estimated GFR (eGFR).1  Relmapirazin is indicated for use with the TGFR.

“The Clinical Kidney Journal study raises serious concerns about how chronic kidney disease is diagnosed today,” said Dr. Ira Kurtz, Chief of the Division of Nephrology at UCLA Medical Center. “Researchers found that current eGFR methods misclassified 35% of patients, leading to potentially incorrect treatments and delayed interventions.”

In the February ahead of print section in the Journal of the American Society of Nephrology (JASN), MediBeacon clinical study data from the use of transdermal detection of relmapirazin in patients with normal to impaired kidney function across a range of skin color types was posted online.2 JASN publishes high-impact research to advance the understanding and treatment of kidney diseases.3

In addition to his leadership role at UCLA Medical Center, Dr. Kurtz is active in the development of an artificial kidney and artificial intelligence in the training and practice of nephrology.

Dr. Kurtz commented that: “The study in the Journal of the American Society of Nephrology introduces a wearable, transdermal device that assesses GFR without the need for blood samples. The fluorescence-based test, developed by MediBeacon, demonstrated an exceptional correlation (r² = 0.90) with plasma mGFR across all skin types, paving the way for more equitable and accurate kidney function assessment. These two new studies have reshaped the landscape of kidney disease diagnostics, offering both a cutting-edge innovation and a stark warning about current practices. The findings underscore the urgent need for improved kidney function assessment tools, with non-invasive, point of care GFR measurement emerging as a game-changing solution.”

“Awareness of kidney disease is relatively low despite the fact that it is the 7th leading risk factor for mortality worldwide.4 MediBeacon is pleased to have the opportunity to aid in the assessment of kidney function in China,” said Steve Hanley CEO of MediBeacon. “NMPA approval is the culmination of a rigorous device application process that required close collaboration of the MediBeacon and Huadong Medicine teams. We look forward to the next phase of our partnership with Huadong Medicine and eagerly anticipate Lumitrace approval in China later this year.”

The TGFR, which includes Lumitrace (relmapirazin), was approved on January 17th by the U.S. Food and Drug Administration (FDA). MediBeacon continues development of future TGFR products including a next-generation TGFR Sensor with updated software and algorithms.

About MediBeacon Inc.
MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon’s use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 55 granted U.S. patents and over 215 granted patents worldwide that provide extensive coverage of the MediBeacon® TGFR, including Lumitrace® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR is approved for human use. Potential technology applications in gastroenterology, ophthalmology and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: www.medibeacon.com.

About Lumitrace® (relmapirazin) injection
Relmapirazin is a non-radioactive, non-iodinated pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al.5

About MediBeacon® Transdermal GFR System (TGFR) 
The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace® (relmapirazin), which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Sensor records 2.5 fluorescent readings per second and the TGFR Monitor will display the average session tGFR reading at the patient’s bedside or in the outpatient setting.

IMPORTANT SAFETY INFORMATION FOR TGFR (U.S. FDA)

Indication for Use:
The MediBeacon® Transdermal GFR System (TGFR) is intended to assess the Glomerular Filtration Rate (GFR) in adult patients with impaired or normal renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent over time. This device has been validated in patients with stable renal function.

The MediBeacon® TGFR is not approved for use in patients with GFR <15 ml/min/1.73 m2, GFR >120 ml/min/1.73m2, patients on dialysis, or anuric patients. The use of this device in patients with dynamic and rapidly changing renal function has not been validated. This device is not intended to diagnose acute kidney injury (AKI).

The MediBeacon® TGFR Sensor and exogenous tracer agent, Lumitrace® injection, are single use and are only used with the MediBeacon® TGFR.

The MediBeacon® TGFR Sensor is a single use device intended to attach to the patient’s skin and excite fluorescence in Lumitrace® injection, the tracer agent, and measure the returning light intensity. The data is sent to the MediBeacon® TGFR Monitor.

Lumitrace® is an injectable exogenous fluorescent tracer indicated for use with the MediBeacon® Transdermal GFR System (TGFR) for Glomerular Filtration Rate assessment.

Contraindications:
There are no known contraindications.

Warnings and Precautions:

  • See ifu.medibeacon.com for full instructions, warnings, and cautions.
  • In clinical studies no serious or severe adverse events have been observed.
  • Lumitrace® injection has light absorbance at 266nm and 435nm, and broad fluorescent emission at ~560nm when excited at ~440nm. Any drug activated at these wavelengths should not be used in conjunction with Lumitrace.
  • Lumitrace injection may interfere with clinical laboratory tests. DO NOT ADMINISTER if the patient is expected to need clinical laboratory testing while Lumitrace is present in their system (up to 72 hours for renally-impaired patients). The presence of Lumitrace decreased B-Type Natriuretic Peptide (BNP) results by around 20% in limited testing.
  • Bolus infusions may impact the GFR assessment temporarily while the vasculature-tissue equilibrium is re-established.
  • During a TGFR session, the patient should be as still as possible, especially during the “Establishing Baseline” stage. The current system is designed to compensate for light activity such as reading or eating after the Baseline stage.

1 CKD stage misclassification between estimated GFR and measured GFR in a clinical study of chronic kidney patients, Clinical Kidney Journal,  Dorshow, Richard B. et al., 2025 Jan 9;18(2):sfaf006. DOI: 10.1093/ckj/sfaf006
2 Glomerular Filtration Rate Measurement Utilizing Transdermal Detection Methodology, Journal of the American Society of Nephrology (JASN), Dorshow, Richard B. et al., February 7, 2025, DOI: 10.1681/ASN.0000000639
3 https://www.asn-online.org/publications/
4 Chronic kidney disease and the global public health agenda: an international consensus, Nature Reviews Nephrology, 20, 473-485 (2024), doi.org/10.1038/s41581-024-00820-6
5 Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102), Kidney International, Volume 106, Issue 4, P679-687, October 2024, DOI: 10.1016/j.kint.2024.06.012

AtHome expands with great determination into the European and American markets, launching the Minix food waste compost dryer

  • Successfully signed an export contract with European home appliance distributor Mares… Initial shipment of thousand units, with plans to increase volume.
  • Targets Europe’s high food waste disposal costs… Minix food waste compost dryer, a compact electric composter, chosen as a strategic solution.
  • Participating in the Chicago Housewares Show (HIS)… Aims to elevate the status of Korean home appliances in the U.S., the heart of the industry.

SEOUL, South Korea, Feb. 25, 2025 /PRNewswire/ — AtHome (CEO Yang Jeong-ho) is gaining momentum both domestically and internationally with its home appliance brand Minix, which aims to maximize space efficiency. Minix’s flagship product, the food waste compost dryer, has sold 150,000 units in South Korea within just 17 months since its launch in September 2023. In light of this success, AtHome has designated the Minix food waste compost dryer as a strategic product for global expansion and has begun securing overseas distribution channels.

Minix food waste compost dryer (Provided by AtHome)
Minix food waste compost dryer (Provided by AtHome)

On February 5, AtHome officially signed an export contract with Mares, a European home appliance distributor with over 40 years of experience and headquartered in Italy. AtHome will supply an initial batch of thousand of Minix food waste compost dryer units, making the product available to European consumers.

AtHome had previously explored entry into the European market by showcasing the Minix food waste compost dryer at the IFA 2024 exhibition in Berlin last September. At the time, the product’s excellent performance, affordable pricing, and sleek, compact design attracted interest from multiple local distributors. Additionally, Europe’s high food waste disposal costs were a key factor that contributed to securing this export deal.

AtHome is also set to participate in The Inspired Home Show 2025, North America’s largest and most prestigious housewares exhibition with a 125-year history. The event will take place from March 2–4 in Chicago, where the company will operate a promotional booth showcasing Minix food waste compost dryer, along with its dishwashers and mini dryers. Given that approximately 40% of food in the U.S. goes to waste, the company anticipates significant consumer interest in its food waste compost dryer, which offers an efficient solution to the country’s ongoing food waste problem.

“AtHome’s recent Series A investment of KRW 18 billion (approximately USD 13.5 million) from major Korean venture capital firms—including Korea Investment Partners, Shinhan Venture Investment, and Hana Ventures—has played a crucial role in accelerating Minix’s global expansion, including its export contract with Mares and participation in international exhibitions,” said CEO Yang Jeong-ho. “We will continue to grow Minix as a leading K-appliance brand that is loved worldwide.”

BUYING SQUARE Opens Experiential Brand Showroom ‘VIBE TWLV’ in Brooklyn

NEW YORK, Feb. 25, 2025 /PRNewswire/ — BUYING SQUARE, operator of the next-generation digital wholesale platform Catalog Shop, unveiled its experiential brand showroom, VIBE TWLV, in Brooklyn, New York. The 4,270-square-foot space on Berry Street in Williamsburg enhances the neighborhood’s vibrant artistic landscape, joining nearby luxury fashion houses such as Hermès and Chanel, and global streetwear retailers like Supreme and Kith.

BUYING SQUARE to open first brand showroom, VIBE TWLV, in New York.
BUYING SQUARE to open first brand showroom, VIBE TWLV, in New York.

Under the concept of “SUPERNORMAL UNIVERSE,” VIBE TWLV is a unique cultural complex that defies conventional retail logic by harmonizing diverse art forms. The name combines “VIBE,” symbolizing complete spiritual communion, and “TWELVE,” considered the most perfect number, to create a compelling spatial narrative. The interior design incorporates signature retail elements while serving as a platform to amplify the creativity of participating artists and designers through regular brand installations and performances.

“VIBE TWLV will be more than a retail space; it’s an authentic artistic hub where brands, artists and cult followings directly participate,” said Evan Choi, founder of VIBE TWLV.

The space features DMX lighting and modern displays that respond dynamically to the background music, creating a captivating visual experience. Movable, independent modular showcases house a curated mix of pieces from global designers, including Martine Rose, KidSuper, Hed Mayner, JUUN.J, RECTO, and Post Archive Faction, and can be reconfigured for runway shows and DJ parties. Sleek, super-mirror metal sculptures and witty furniture designs in striking colors add distinct energy to the space. A centrally located mystery box promises intriguing interactions between shoppers and the environment, ultimately focusing on facilitating brand growth while embracing designers’ aspirations for innovation and originality.

This year, VIBE TWLV plans to spotlight emerging South Korean fashion brands, designers, and artists with distinctive voices in New York, a global fashion capital. Through experiential retail strategies, the showroom aims to boost brand recognition and serve as a launchpad for international market entry, leveraging precise insights and in-depth analysis of segmented global fashion consumer demands. Beginning February 28, the space will host the ‘URBAN KAWAII: HYPER-HYBRID’ exhibition in collaboration with Gallery STAN, showcasing works by six of Korea’s leading pop art creators.

VIBE TWLV, which has redefined experiential retail by establishing a dynamic commercial and cultural hub in Williamsburg, recently received the ‘Asia Design Prize 2025‘ in recognition of its innovative spatial adaptability and forward-thinking design. Standout features of the space include a naturally lit VIP room for private shopping experiences, an infinity room encased in infinite lighting and three-sided mirrors, outdoor signage employing LED animation boxes, and interior displays showcasing immersive video art by graphic artist Deok-hyeong Lee (DHL).

VIBE TWLV SHOWROOM NEW YORK
50 BERRY STREET, BROOKLYN, NEW YORK

About BUYING SQUARE

BUYING SQUARE, an innovative South Korean startup, operates Catalog Shop, a B2B solution based on digital product catalogs that addresses inefficiencies in traditional wholesale trading. Catalog Shop is a next-generation brand wholesale platform that visualizes original wholesale product information through standardized product catalog creation and provides comprehensive brand wholesale process management. Using proprietary AI technology, it automatically generates standardized product catalogs from unstructured brand wholesale product data including Excel, PDF, and image files. Global buyers can select their preferred language and currency on Catalog Shop and immediately add desired products to their cart for ordering.

Leveraging partnerships with numerous brands and wholesalers, along with distinctive big data refinement technology, BUYING SQUARE achieved transactions worth KRW 8 billion (approximately USD 5.5M) in its first year and surpassed KRW 140 billion (approximately USD 97M) in cumulative transactions by 2024, its fifth year of operation.

In October 2024, BUYING SQUARE became the first Korean B2B distribution company to open a 4,270-square-foot experiential brand showroom, ‘VIBE TWLV,’ in Williamsburg, Brooklyn. As a total platform integrating fashion with comprehensive cultural arts, ‘VIBE TWLV’ hosts diverse regular events including exhibitions, concerts, fashion shows, parties, and order sessions. The showroom maximizes offline spatial flexibility through easily dismantled, transported, and reassembled modular furniture and fixtures. This year, BUYING SQUARE plans to expand its global brand and buyer network through brand incubation, creative content collaborations, and promising K-brand exhibitions and runways utilizing this space.

Headquartered in Seoul, the company also operates offices in New York, Shanghai, Tokyo, and Kowloon.

Website: official.buying-square.com/en

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 25TH

NEW YORK, Feb. 25, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 25TH

Trinity Chavez delivers the pre-market update on February 25th

  • Markets await release of this morning’s Consumer Confidence Index
  • Friday’s PCE Index to provide insights on future Fed policy
  • New home sales data and jobless claims to release later this week

Watch NYSE TV Live every weekday 9:00-10:00am ET 

Video – https://mma.prnasia.com/media2/2627318/NYSE_Feb_25_Market_Update.mp4 

 

BTCS Inc. Announces Strategic Partnership and Investment in ETHGas to Grow Market Share and Support Scaling Ethereum Through Realtime Transactions

Silver Spring, Maryland – Newsfile Corp. – February 25, 2025 – BTCS Inc. (NASDAQ: BTCS) (“BTCS” or the “Company”), a leader in blockchain infrastructure and technology, is pleased to announce a strategic partnership with ETHGas, where BTCS will serve as a Priority Builder. As part of this collaboration, BTCS also made a $250,000 investment into ETHGas. This partnership and investment aligns with BTCS’s strategy to not only increase its market share but also expand the overall market size. This initiative is intended to unlock ultra-low-latency scaling on Ethereum’s blockchain, enabling transaction confirmations approximately 100 times faster than Solana.

The ETHGas investment was structured as a SAFT (Simple Agreement for Future Tokens) and designates BTCS as a Priority Builder. This exclusive role is granted to builders with proven expertise in low-latency block construction and robust order flow capabilities. As a Priority Builder, BTCS is strategically positioned to expand its influence over blockspace and grow its market share.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11377/241789_d71ea94ab4bf0a33_002full.jpg

“As a pioneer in blockchain infrastructure and digital asset innovation, BTCS is thrilled to partner with ETHGas to expand the overall market of fee-based products, to drive revenue for BTCS while helping make Ethereum transactions more efficient and cost-effective for the ecosystem,” said Charles Allen, CEO of BTCS. “Our investment in ETHGas aligns with our strategy to drive scalable revenue growth and improve margins by expanding order flow, refining our tech stack, and controlling block space. Our planned ETHGas integration should help achieve this goal by increasing both order flow and block space.”

Cannot view this video? Visit:
https://www.youtube.com/watch?v=GPdYx3gQYQE

ETHGas re-engineers the Ethereum pipeline for block construction enabling Validators to sell blockspace in advance of the spot block auction. On one side of the marketplace, ETHGas provides certainty to Validators, and on the other side, it provides an array of precision order execution products for end-users, like traders, to customize their access to blockspace. By enabling 3 millisecond blockspace confirmations and instruments to hedge gas price volatility, ETHGas creates a real-time, gasless Ethereum, where the handling and trading of gas is largely relegated to the background among institutional players. ETHGas has partnered with builders representing over 90% of the market, and is working with the majority of validators to ensure broad network participation and adoption.

ETHGas Founder Kevin Lepsoe expressed enthusiasm, stating, “BTCS’s partnership validates our mission to open up and democratize access to blockspace. This collaboration helps pave the way for a much faster, more efficient Ethereum enabling transaction costs or ‘gas prices’ to be risk-managed within a traditional commodity risk-management framework.” He continued, “Together with BTCS, we enhance accessibility, in particular, to global Asset Managers as they look to scale their ETH and Staked ETH Fund offerings.

About BTCS:
BTCS Inc. (NASDAQ: BTCS) is a U.S.-based blockchain infrastructure technology company currently focused on driving scalable revenue growth through its blockchain infrastructure operations. BTCS has honed its expertise in blockchain network operations, particularly in block building and validator node management. Its branded block-building operation, Builder+, leverages advanced algorithms to optimize block construction for on-chain validation, thus maximizing gas fee revenues. BTCS also supports other blockchain networks by operating validator nodes and staking its crypto assets across multiple proof-of-stake networks, allowing crypto holders to delegate assets to BTCS-managed nodes. In addition, the Company has developed ChainQ, an AI-powered blockchain data analytics platform, which enhances user access and engagement within the blockchain ecosystem. Committed to innovation and adaptability, BTCS is strategically positioned to expand its blockchain operations and infrastructure beyond Ethereum as the ecosystem evolves. Explore how BTCS is revolutionizing blockchain infrastructure in the public markets by visiting www.btcs.com.

For more information follow us on:

Twitter: https://x.com/NasdaqBTCS
LinkedIn: https://www.linkedin.com/company/nasdaq-btcs
Facebook: https://www.facebook.com/NasdaqBTCS

About ETHGas
ETHGas is a blockchain technology company dedicated to institutionalizing Ethereum’s gas markets through low latency infrastructure, and a broad suite of risk management instruments. By providing structure to the gas markets, ETHGas brings certainty and predictability to validators, block builders, traders, decentralized applications (DApps) and scalability to Ethereum at large. The ETHGas Protocol Token (GASS) serves as a key component of the ecosystem providing governance to the broad set of participants that interact with blockspace on Ethereum.

For more information, visit www.ethgas.com. The information contained on, or accessible through, this website is not incorporated by reference into this press release, and you should not consider it part of this press release.

Forward-Looking Statements:
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including statements regarding our ability to grow market share, drive revenue, increasing both order flow and block space and improve margins by expanding order flow. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon assumptions and are subject to various risks and uncertainties, including without limitation regulatory issues, cybersecurity risks, technological challenges, market adoption risks, competition, changes in blockchain protocols, unexpected issues with Builder+ or ChainQ, the reluctance of validators to utilize our Builder+ product, volatility in cryptocurrency markets, and other risks inherent to blockchain technology and cryptocurrency operations, as well as risks set forth in the Company’s filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2023 which was filed on March 21, 2024. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements, whether as a result of new information, future events, or otherwise, except as required by law.

BTCS Investor Relations:
Charles Allen – CEO
X (formerly Twitter): @Charles_BTCS
Email: ir@btcs.com

ETHGas Public Relations:
Kevin Lepsoe – Founder
X (formerly Twitter) @lepsoe
Email: ir@ethgas.com

The issuer is solely responsible for the content of this announcement.

SunCar Technology Addresses National Automotive Circulation Industry Forum, Showcasing Digital Solutions for Dealers

NEW YORK, Feb. 25, 2025 /PRNewswire/ — SunCar Technology Group Inc. (“SunCar” or the “Company”) (NASDAQ: SDA), an innovative leader in auto e-insurance and cloud-based B2B auto services in China, participated in the National Automotive Circulation Industry New Year Forum and Consumer Promotion Conference in Beijing. The Company, serving as a vice president unit of the National Automotive Circulation Industry Association, was represented by Vice President Gu Saiye, who delivered a keynote address highlighting SunCarOnline’s technological solutions that help dealers enhance customer retention, renewal rates, and profitability.

The conference brought together over 400 industry stakeholders, including automotive dealer groups, manufacturers, pre-owned vehicle enterprises, financial and insurance institutions, aftermarket service providers, and automotive trade association representatives from across China. Attendees examined industry development trends and consumer promotion strategies, analyzed market conditions, and discussed implementing the 2025 auto trade-in policy to stimulate the automotive consumer market.

In her presentation, Vice President Gu detailed how SunCar Technology enhances dealer competitiveness through its “SunCarInsurance” platform and showcased successful case studies integrating auto insurance into customer lifecycle management. The Company’s technological solutions enable dealers to implement seamless sales and after-sales management, improving customer retention and remarketing efficiency. SunCar’s “Car Butler” service and cloud-based customer service platform provide comprehensive dealer support while enhancing customer satisfaction and loyalty, thereby increasing renewal rates, claim rates, and service retention, all contributing to improved profitability.

“Our commitment remains focused on advancing the automotive circulation industry through technological innovation,” stated Gu Saiye. “SunCar Technology will continue strengthening our dealer partnerships, expanding our solution offerings, and supporting high-quality industry development.”

Conference participants commended SunCar Technology’s innovations in auto insurance and customer lifecycle management as setting industry standards. Multiple dealer representatives expressed interest in deepening their collaboration with SunCar Technology to accelerate digital transformation within the automotive circulation industry.

The forum established a valuable platform for industry dialogue and collaboration while outlining strategic directions for the automotive circulation industry in 2025. SunCar Technology will continue leveraging its technological capabilities and industry partnerships to address emerging opportunities and challenges.

About SunCar Technology Group Inc.

Founded in 2007, SunCar is transforming the customer journey for auto services and auto insurance in China, the largest passenger vehicle market in the world. SunCar develops and operates cloud-based platforms that seamlessly connect drivers with a wide range of auto services and insurance coverage options through a nationwide network of sales partners. As a result, SunCar has established itself as the leader in China in the B2B auto services market and the auto eInsurance market for electric vehicles. The Company’s intelligent cloud platform empowers its enterprise clients to access and manage their customer database and offerings optimally, and drivers gain access to hundreds of services from tens of thousands of independent providers in a single application. For more information, please visit https://suncartech.com.

Forward-Looking Statements

This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.

Contact Information:

SunCar:
Investor Relations: Ms. Hui Jiang
Email: IR@suncartech.com
Legal: Ms. Li Chen
Email: chenli@suncartech.com

U.S. Investor Relations
Matthew Abenante, IRC
President
Strategic Investor Relations, LLC
Tel: 347-947-2093
Email: matthew@strategic-ir.com

 

Foxit Supercharges AI Assistant with Multi-Document Analysis on iOS & Android

Enables Users to Boost Productivity with AI-Powered Summaries, Cross-Document Insights, and Instant Data Extraction Across Mobile Device

FREMONT, Calif., Feb. 25, 2025 /PRNewswire/ — Foxit, a leading provider of innovative PDF and eSignature products and services, helping knowledge workers to increase productivity and do more with documents, today announced the addition of multi-document analysis to its AI Assistant feature within its mobile apps for iOS and Android. This new and unique capability enhances the AI Assistant’s functionality, enabling users to analyze multiple documents simultaneously directly from their mobile devices.

The introduction of multi-document analysis caters to the evolving needs of professionals who require efficient tools to manage and process large volumes of information. The new feature is designed to simplify workflows by allowing users to:

  • Summarize Multiple Documents at Once: Create concise summaries for all uploaded documents, saving time by avoiding the need to review each individually.
  • Ask Questions Across Files: Get answers that draw insights from multiple documents simultaneously, ideal for comparing contracts, reports, or research materials.
  • Extract Key Information: Pinpoint critical data, such as deadlines or figures, or find patterns and trends from across multiple files in seconds.

Whether you’re a legal professional reviewing case files, a researcher analyzing studies, or a business leader comparing proposals, the AI Assistant’s Multi-Document Analysis feature ensures greater productivity and smarter decision-making anytime and anywhere.

The multi-document analysis feature is now available in the latest update to Foxit’s PDF Reader and PDF Editor mobile apps for iOS and Android.

“People just don’t have time to sift through a pile of documents one by one anymore… especially on their phones,” said Evan Reiss, VP, Head of Marketing, Foxit. “With multi-document analysis in our AI Assistant, you can get summaries, pull key details, and ask questions across multiple files all at once. It’s about working smarter, not harder – and making sure you have the info you need, right when you need it.”

For more information about Foxit’s AI solutions, please visit https://www.foxit.com/ai-pdf/.

About Foxit
Foxit is a leading provider of innovative PDF and eSignature products and services, helping knowledge workers to increase their productivity and do more with documents. Foxit delivers easy-to-use desktop software, mobile apps, and cloud services that allow users to create, edit, fill, and sign documents through their integrated PDF Editor and eSign offerings. Foxit enables software developers to incorporate innovative PDF technology into their applications via powerful, multi-platform Software Developer Kits (SDK).

Foxit has sold to over 640,000 customers, ranging from SMBs to global enterprises, located in more than 200 countries. The company has offices worldwide, including locations in the U.S., Europe, Australia, and Asia. For more information, please visit https://foxit.com.

PR Contact:
Nicole Gorman
Touchdown PR, for Foxit
508-397-0131
foxit@touchdownpr.com